Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The impact of liver cirrhosis (LC) on the clinical outcomes of patients with coronavirus disease 2019 (COVID-19) remains elusive. This study evaluated the association between LC and the development of severe complications from COVID-19. Methods: We used the National Health Insurance claims data of Korea. We included 234,427 patients older than 19 years who tested for severe acute respiratory syndrome coronavirus 2. Patients with LC who were infected with COVID-19 (n = 67, LC+ COVID+) were matched with those with cirrhosis only (n = 332, LC+ COVID–) and those with COVID-19 only (n = 333, LC– COVID+) using a propensity score in a 1:5 ratio. The primary outcome was the development of severe complications. Results: Of the matched patients, the mean age was 60 years and 59.7% were male. Severe complications occurred in 18, 54, and 60 patients in the LC+ COVID+, LC+ COVID–, and LC– COVID+ groups, respectively. After adjusting for comorbidities, there was no significant difference in the risk of developing severe complications from COVID-19 between the LC+ COVID+ and LC– COVID+ groups but significant difference exists between the LC+ COVID+ and LC+ COVID–. Older age, hypertension, cancer, chronic obstructive pulmonary disease, and a higher Charlson comorbidity index were associated with a higher risk of severe complications in patients with cirrhosis and COVID-19. Conclusions: Our study suggests that LC was not independently associated with the development of severe complications, including mortality, in patients with COVID-19. Our results need to be evaluated through a large, prospective study.
Abstract
Background/Aims: The impact of liver cirrhosis (LC) on the clinical outcomes of patients with coronavirus disease 2019 (COVID-19) remains elusive. This study evaluated the association between LC and the development of severe complications from COVID-19. Methods: We used the National Health Insurance claims data of Korea. We included 234,427 patients older than 19 years who tested for severe acute respiratory syndrome coronavirus 2. Patients with LC who were infected with COVID-19 (n = 67, LC+ COVID+) were matched with those with cirrhosis only (n = 332, LC+ COVID–) and those with COVID-19 only (n = 333, LC– COVID+) using a propensity score in a 1:5 ratio. The primary outcome was the development of severe complications. Results: Of the matched patients, the mean age was 60 years and 59.7% were male. Severe complications occurred in 18, 54, and 60 patients in the LC+ COVID+, LC+ COVID–, and LC– COVID+ groups, respectively. After adjusting for comorbidities, there was no significant difference in the risk of developing severe complications from COVID-19 between the LC+ COVID+ and LC– COVID+ groups but significant difference exists between the LC+ COVID+ and LC+ COVID–. Older age, hypertension, cancer, chronic obstructive pulmonary disease, and a higher Charlson comorbidity index were associated with a higher risk of severe complications in patients with cirrhosis and COVID-19. Conclusions: Our study suggests that LC was not independently associated with the development of severe complications, including mortality, in patients with COVID-19. Our results need to be evaluated through a large, prospective study.
참고문헌 (35)
- Del Rio C, "2019 Novel coronavirus : important information for clinicians", JAMA, 323, pp.1039~1040 (2020)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Bhatraju PK, "Covid-19 in critically ill patients in the Seattle region : case series", N Engl J Med, 382, pp.2012~2022 (2020)
- "People of any age with underlying medical conditions" (2020)[URL]
- Grasselli G, "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", JAMA, 323, pp.1574~1581 (2020)
- Dai M, "Patients with cancer appear more vulnerable to SARS-CoV-2 : a multicenter study during the COVID-19 outbreak", Cancer Discov, 10, pp.783~791 (2020)
- Kumar-M P, "Coronavirus disease(COVID-19)and the liver : a comprehensive systematic review and meta-analysis", Hepatol Int, 14, pp.711~722 (2020)
- Richardson S, "Presenting characteristics, comorbidities, and outcomes among 5700patients hospitalized with COVID-19 in the New York city area", JAMA, 323, pp.2052~2059 (2020)
- Albillos A, "Cirrhosis-associated immune dysfunction : distinctive features and clinical relevance", J Hepatol, 61, pp.1385~1396 (2014)
- Moon AM, "High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis : preliminary results from an international registry", J Hepatol, 73, pp.705~708 (2020)
- Bajaj JS, "Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone : multicentre matched cohort", Gut (2020)
- Iavarone M, "High rates of 30-day mortality in patients with cirrhosis and COVID-19", J Hepatol, 73, pp.1063~1071 (2020)
- Singh S, "Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States : a multicenter research network study", Gastroenterology, 159, pp.768~771 (2020)
- Gao F, "The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research", J Hepatol, 73, pp.1568~1569 (2020)
- Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
- Chung W, "Liver cirrhosis and cancer : comparison of mortality", Hepatol Int, 12, pp.269~276 (2018)
- De Groot V, "How to measure comorbidity : a critical review of available methods", J Clin Epidemiol, 56, pp.221~229 (2003)
- Jung SY, "Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19). Related outcomes in Korea: a nationwide population-based cohort study", Clin Infect Dis, 71, pp.2121~2128 (2020)
- Son M, "Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea", Hypertension, 76, pp.742~749 (2020)
- Oh H, "Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B", Aliment Pharmacol Ther, 52, pp.371~381 (2020)
- Wong GL, "Management of patients with liver derangement during the COVID-19pandemic : an Asia-Pacific position statement", Lancet Gastroenterol Hepatol, 5, pp.776~787 (2020)
- Garrido I, "Review article. COVID-19and liver disease: what we know on 1st May 2020", Aliment Pharmacol Ther, 52, pp.267~275 (2020)
- Bijlsma JW, "Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination(U-Act-Early) : a multicentre, randomised, double-blind, double-dummy, strategy trial", Lancet, 388, pp.343~355 (2016)
- Palacios R, "Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir", ritonavir, 2006, pp.7, 319~323
- Grein J, "Compassionate use of remdesivir for patients with severe COVID-19", N Engl J Med, 382, pp.2327~2336 (2020)
- Weber S, "Severe liver failure during SARS-CoV-2 infection", Gut, 69, pp.1365~1367 (2020)
- Berenguer J, "Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain", Clin Microbiol Infect, 26, pp.1525~1536 (2020)
- Ji D, "Effect of COVID-19 on patients with compensated chronic liver diseases", Hepatol Int, 14, pp.701~710 (2020)
- Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population", Hepatology, 66, pp.1454~1463 (2017)
- Boettler T, "Impact of COVID-19 on the care of patients with liver disease : EASL-ESCMID position paper after 6 months of the pandemic", JHEP Rep, 2, pp.100169~ (2020)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Zhou YJ, "Younger patients with MAFLD are at increased risk of severe COVID-19 illness : a multicenter preliminary analysis", J Hepatol, 73, pp.719~721 (2020)
- Docherty AB, "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study", BMJ, 369, pp.m1985~ (2020)
- Cai Q, "Obesity and COVID-19 severity in a designated hospital in Shenzhen, China", Diabetes Care, 43, pp.1392~1398 (2020)
- Lee SW, "Severe clinical outcomes of COVID-19 associated with proton pump inhibitors : a nationwide cohort study with propensity score matching", Gut (2020)